After regulatory delays and manufacturing issues caused Bristol Myers Squibb investors to miss out on Celgene contingent value rights, the closely watched CAR-T drug liso-cel has scored an FDA nod.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results